Genelux (NASDAQ:GNLX – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Risk and Volatility
Genelux has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.
Earnings and Valuation
This table compares Genelux and Senti Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $10,000.00 | 8,459.88 | -$32.15 million | ($0.86) | -2.17 |
| Senti Biosciences | $20,000.00 | 218.05 | -$61.44 million | ($1.77) | -0.08 |
Genelux has higher earnings, but lower revenue than Senti Biosciences. Genelux is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Genelux and Senti Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -205.85% | -138.79% |
| Senti Biosciences | N/A | -1,629.80% | -119.72% |
Insider & Institutional Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for Genelux and Senti Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
| Senti Biosciences | 1 | 0 | 1 | 1 | 2.67 |
Genelux presently has a consensus price target of $20.00, indicating a potential upside of 969.52%. Senti Biosciences has a consensus price target of $9.00, indicating a potential upside of 6,328.57%. Given Senti Biosciences’ higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Genelux.
Summary
Genelux beats Senti Biosciences on 8 of the 13 factors compared between the two stocks.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
About Senti Biosciences
Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
